Teva Pharmaceutical Is Getting a Beating Between Analysts and Credit Rating Agencies Who See Valuation Heading Down the Drain


Teva Pharmaceutical (NYSE:TEVA) investors have seen a once strong Israeli pharma giant stumble 71% from its former valuation glory, and some on the Street fear another 50% fall from grace is still coming investors’ way. HSBC  analyst Steve McGarry and Wells Fargo analyst Davis Maris prepare for the worst.

Story Continues